The First Generation of β-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Angewandte Chemie International Edition Année : 2012

The First Generation of β-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy

Résumé

Galactoside prodrugs have been designed that can be selectively activated by lysosomal β-galactosidase located inside cancer cells expressing a specific tumor-associated receptor. This efficient enzymatic process triggers a potent cytotoxic effect, releasing the potent antimitotic agent MMAE and allowing the destruction of both receptor-positive and surrounding receptor-negative tumor cells.

Dates et versions

hal-00736090 , version 1 (27-09-2012)

Identifiants

Citer

Thibaut Legigan, Jonathan Clarhaut, Isabelle Tranoy-Opalinski, Arnaud Monvoisin, Brigitte Renoux, et al.. The First Generation of β-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy. Angewandte Chemie International Edition, 2012, 51, pp.1 - 6. ⟨10.1002/anie.201204935⟩. ⟨hal-00736090⟩
97 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More